Information Provided By:
Fly News Breaks for November 4, 2019
Nov 4, 2019 | 08:48 EDT
Canaccord analyst Arlinda Lee initiated coverage of BioNTech with a Buy rating as the company seeks to deliver immunotherapy personalized for each patient's immune system, genetic background, and tumor characteristics. The company has eight clinical drug candidates, six partnerships, and the potential to generate many more therapeutic candidates. Lee has a $22 price target on BioNTech shares.